Michael C. Sierant

Michael C. Sierant

Auto-generated profile, based on publicly available information

Michael C. Sierant

BioMarin Pharmaceutical, San Rafael, CA 94901, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
XZXue Zeng
Xue Zeng
MSMichael C. Sierant
Michael C. Sierant
MKMichael C. Kruer
Michael C. Kruer

29 April 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
LSLihong Shi
Lihong Shi
YLYu-Hsuan Lin
Yu-Hsuan Lin
MSM. C. Sierant
M. C. Sierant
FZFan Zhu
Fan Zhu
SCShuaiying Cui
Shuaiying Cui
JEJames Douglas Engel
James Douglas Engel
To globally survey the changes in transcriptional landscape during terminal erythroid differentiation, we performed RNA sequencing (RNA-seq) on primary human CD34+ cells after ex vivo differentiation from the earliest into the most mature erythroid cell stages. This analysis identified thousands of novel intergenic and intronic transcripts as well as novel alternative transcript isoforms. After rigorous data filtering, 51 (presumptive) novel protein-coding transcripts, 5326 long and 679 small non-coding RNA candidates remained. The analysis also revealed two clear transcriptional trends during terminal erythroid differentiation: first, the complexity of transcript diversity was predominantly achieved by alternative splicing, and second, splicing junctional diversity diminished during erythroid differentiation. Finally, 404 genes that were not known previously to be differentially expressed in erythroid cells were annotated. Analysis of the most extremely differentially expressed transcripts revealed that these gene products were all closely associated with hematopoietic lineage differentiation. Taken together, this study will serve as a comprehensive platform for future in-depth investigation of human erythroid development that, in turn, may reveal new insights into multiple layers of the transcriptional regulatory hierarchy that controls erythropoiesis.

26 February 2015 in Blood
Verified
Journal Article
Open access
PDF file
SCShuaiying Cui
Shuaiying Cui
OTOsamu Tanabe
Osamu Tanabe
MSMichael Sierant
Michael Sierant
LSLihong Shi
Lihong Shi
ACAndrew Campbell
Andrew Campbell
JEJames Douglas Engel
James Douglas Engel
Key Points: Conditional TR2/TR4 knockout leads to induction of murine embryonic globin genes.

31 December 2018 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
MSMichael C. Sierant
Michael C. Sierant
JCJungmin Choi
Jungmin Choi
Tumor heterogeneity, the cellular mosaic of multiple lineages arising from the process of clonal evolution, has continued to thwart multi-omics analyses using traditional bulk sequencing methods. The application of single-cell sequencing, in concert with existing genomics methods, has enabled high-resolution interrogation of the genome, transcriptome, epigenome, and proteome. Applied to cancers, these single-cell multi-omics methods bypass previous limitations on data resolution and have enabled a more nuanced understanding of the evolutionary dynamics of tumor progression, immune evasion, metastasis, and treatment resistance. This review details the growing number of novel single-cell multi-omics methods applied to tumors and further discusses recent discoveries emerging from these approaches, especially in regard to immunotherapy.

8 May 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
LSLihong Shi
Lihong Shi
MSM. C. Sierant
M. C. Sierant
KGKatherine Gurdziel
Katherine Gurdziel
FZFan Zhu
Fan Zhu
SCShuaiying Cui
Shuaiying Cui
JEJames Douglas Engel
James Douglas Engel
We previously reported that TR2 and TR4 orphan nuclear receptors bind to direct repeat (DR) elements in the ε- and γ-globin promoters, and act as molecular anchors for the recruitment of epigenetic corepressors of the multifaceted DRED complex, thereby leading to ε- and γ-globin transcriptional repression during definitive erythropoiesis. Other than the ε- and γ-globin and the GATA1 genes, TR4-regulated target genes in human erythroid cells remain unknown. Here, we identified TR4 binding sites genome-wide using chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq) as human primary CD34+ hematopoietic progenitors differentiated progressively to late erythroid precursors. We also performed whole transcriptome analyses by RNA-seq to identify TR4 downstream targets after lentiviral-mediated TR4 shRNA knockdown in erythroid cells. Analyses from combined ChIP-seq and RNA-seq datasets indicate that DR1 motifs are more prevalent in the proximal promoters of TR4 direct target genes, which are involved in basic biological functions (e.g., mRNA processing, ribosomal assembly, RNA splicing and primary metabolic processes). In contrast, other non-DR1 repeat motifs (DR4, ER6 and IR1) are more prevalent at gene-distal TR4 binding sites. Of these, approximately 50% are also marked with epigenetic chromatin signatures (such as P300, H3K27ac, H3K4me1 and H3K27me3) associated with enhancer function. Thus, we hypothesize that TR4 regulates gene transcription via gene-proximal DR1 sites as TR4/TR2 heterodimers, while it can associate with novel nuclear receptor partners (such as RXR) to bind to distant non-DR1 consensus sites. In summary, this study reveals that the TR4 regulatory network is far more complex than previously appreciated and that TR4 regulates basic, essential biological processes during the terminal differentiation of human erythroid cells. Sequential genome-wide binding studies investigated by deep sequencing (ChIP-seq) represent a powerful tool for investigating the temporal sequence of gene activation and repression events that take place as cells differentiate. Here, we report the binding of an “orphan” nuclear receptor (one for which no ligand has been identified) to its cognate genomic regulatory sites and perform the functional analysis to validate its downstream targets as precursor cells differentiate from very early human hematopoietic progenitors into red blood cells. We discovered that when this receptor is bound at gene proximal promoters, it recognizes a different DNA sequence than when it binds to more distant regulatory sites (enhancers and silencers). Since this receptor can either activate or repress specific target genes, the data suggest the intriguing possibility that the two different modes of DNA recognition may reflect association of the receptor with different partner molecules when regulating gene expression from proximal or distal sequences.

11 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
XZXue Zeng
Xue Zeng
MSMichael C. Sierant
Michael C. Sierant
MKMichael C. Kruer
Michael C. Kruer